The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Colecalciferol (Fultium-D3®) has been accepted for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.
Fingolimod (Gilenya®) has been accepted for restricted use following a resubmission. Fingolimod can be used as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) in adults. Use is restricted to individuals with a high disease activity despite treatment with a beta-interferon and an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year. Continued access is also contingent upon the availability of the patient access scheme that improves cost-effectiveness.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Tiotropium trialled in asthma||MUR service changes »|